SCHEMBL262673

SCHEMBL262673

CCC(C(=O)O)c1ccccc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.45
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP2C19 P33261 2/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP26A1 O43174 1/20 0.37
AKR1C3 P42330 4/20 0.37
AKR1C2 P52895 4/20 0.37
AKR1C1 Q04828 1/20 0.37
PTGS1 P23219 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
HDAC3 O15379 3/20 0.37
HDAC4 P56524 3/20 0.37
HDAC1 Q13547 3/20 0.37
HDAC7 Q8WUI4 3/20 0.37
HDAC2 Q92769 3/20 0.37
HDAC10 Q969S8 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylformamide SCHEMBL28337539 0.89 HTT (0.38) HTTLMNAHSD17B10CYP2C19CYP2C9
SCHEMBL3138036 0.84 HTT (0.44) HTTLMNAHSD17B10CYP2C19CYP2C9
SCHEMBL29279682 0.83 HTT (0.41) HTTHSD17B10ALDH1A1POLBHDAC3
SCHEMBL1492655 0.82 HTT (0.46) HTTCYP2C19CYP2C9TSHRCYP1A2
SCHEMBL25816145 0.81 CYP1A2 (0.57) HTTHSD17B10CYP2C19CYP2C9TSHR
SCHEMBL9157016 0.81 PIN1 (0.46) HTTCYP2C19CYP2C9TSHRPOLB
SCHEMBL4062734 0.79 LMNA (0.41) LMNAHSD17B10CYP2C19TSHRCYP1A2
SCHEMBL4071095 0.79 TSHR (0.57) LMNAHSD17B10TSHRCYP1A2AKR1C3
SCHEMBL6773227 0.79 TSHR (0.57) LMNAHSD17B10TSHRCYP1A2AKR1C3
SCHEMBL1928791 0.79 ACP3 (0.43) LMNAHSD17B10CYP2C19CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118768579-A Preparation method and application of monodisperse silver nanoparticles 丽水学院 2024-10-15 CN claimed
CN-101380317-B Pharmaceutical composition for relieving pruritus CAYMAN ISLAND SHANGANSHENG DEV PHARMACEUTICAL CO LTD 2010-12-08 CN claimed
EP-2033635-A1 Short-chain fatty acid derivatives for treating pruritus Asan Laboratories Company (Cayman) Limited (CN) 2009-03-11 EP claimed
CN-101380317-A Pharmaceutical composition for relieving pruritus CAYMAN ISLAND SHANGANSHENG DEV (CN) 2009-03-11 CN claimed
US-20080107646-A1 Administering phenylbutyric acid derivative and pharmaceutically acceptable carrier Sunny Pharmtech Inc. (TW) 2008-05-08 US claimed
US-6403646-B1 ADMINISTERING PHENYLBUTYRIC ACID OR DERIVATIVES TO TREAT LIVER DISEASE AND EMPHYSEMA CAUSED BY PROTEASE INHIBITOR TYPE Z MUTATION; STIMULATES SECRETION WITHOUT INCREASING SYNTHESIS OF PROTEIN PERLMUTTER DAVID H (US) 2002-06-11 US claimed
US-12404295-B2 (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2025-09-02 US disclosed
CN-118768579-A Preparation method and application of monodisperse silver nanoparticles 丽水学院 2024-10-15 CN disclosed
EP-4010076-B1 (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2024-01-17 EP disclosed
US-20220315619-A1 (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2022-10-06 US disclosed
CN-114702630-A Lignin-based polymer and preparation method and application thereof 中国林业科学研究院林产化学工业研究所 2022-07-05 CN disclosed
CN-111777540-B Method for synthesizing pyrrolidone compound by continuous light-induced catalysis 南京工业大学 2021-09-24 CN disclosed
CN-111777540-A Method for synthesizing pyrrolidone compound by continuous light-induced catalysis 南京工业大学 2020-10-16 CN disclosed
EP-0353248-A1 METHOD FOR RESOLUTION OF STEREOISOMERS IN MULTIPHASE AND EXTRACTIVE MEMBRANE REACTORS. SEPRACOR INC (US) 1990-02-07 EP disclosed
US-4800162-A ENZYME-ACTIVATED MEMBRANE SEPRACOR, INC. (US) 1989-01-24 US disclosed
WO-1988007582-A1 METHOD FOR RESOLUTION OF STEREOISOMERS IN MULTIPHASE AND EXTRACTIVE MEMBRANE REACTORS SEPRACOR, INC. (US) 1988-10-06 WO disclosed
US-4288453-A A-(1-PHENYL-2,2,2-TRIFLUOROETHOXY (OR -ETHYLTHIO))ALKANOIC ACIDS USEFUL AS ANTICHOLESTEROL AND ANTILIPEMIC AGENTS SCIENCE UNION ET CIE (FR) 1981-09-08 US disclosed
US-4118393-A Phenyl azabicyclohexanones AMERICAN CYANAMID COMPANY (US) 1978-10-03 US disclosed
US-4001233-A CNS STIMULANTS, MUSCLE RELAXANTS E. R. SQUIBB & SONS, INC. (US) 1977-01-04 US disclosed
US-3957787-A CENTRAL NERVOUS SYSTEM STIMULANTS, MUSCLE RELAXANTS E. R. SQUIBB & SONS, INC. (US) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315619-A1 (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES LGALS1, LGALS3, LGALS2 HTT 1755/4885LMNA 1963/4885HSD17B10 2291/4885
US-12404295-B2 (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives LGALS1, LGALS3, LGALS2 HTT 1755/4885LMNA 1963/4885HSD17B10 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.